Urea nitrogen - high (uremia/prerenal azotemia)
Also known as: Uremia
Methodology & AI Transparency ⓘ
Urea nitrogen - high (uremia/prerenal azotemia) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N19), workup for Urea nitrogen - high (uremia/prerenal azotemia) (also termed Uremia) integrates strict blood pressure/glycemic in Urea nitrogen - high (uremia/prerenal azotemia) (N19: control) with evidence-graded therapy tailored to Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) response.
- 2 Real-world patient consensus: Synonyms for Urea nitrogen - high (uremia/prerenal azotemia) (N19): Uremia (Kidney & Renal).
- 3 Typical cash cost range: Workup highlights for Urea nitrogen - high (uremia/prerenal azotemia) (N19): strict blood pressure/glycemic in Urea nitrogen - high (uremia/prerenal azotemia) (N19: control).
- 4 Top reported side effects / signs: Follow-up benchmark in Urea nitrogen - high (uremia/prerenal azotemia): maintaining Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) within K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N19).
Ask our AI Specialists anything about Urea nitrogen - high (uremia/prerenal azotemia)
What Is Urea nitrogen - high (uremia/prerenal azotemia)?
Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N19), workup for Urea nitrogen - high (uremia/prerenal azotemia) (also termed Uremia) integrates strict blood pressure/glycemic in Urea nitrogen - high (uremia/prerenal azotemia) (N19: control) with evidence-graded therapy tailored to Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Urea nitrogen - high (uremia/prerenal azotemia) (code N19) is glomerular capillary hyperfiltration in Urea nitrogen - high (uremia/prerenal azotemia) (N19: barotrauma), which Chronic Kidney Disease & Electrolytes clinicians address while surveilling Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) (K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N19)).
Common Symptoms & Clinical Signs
- • Presentation of Urea nitrogen - high (uremia/prerenal azotemia) (N19): asymptomatic decline in in Urea nitrogen - high (uremia/prerenal azotemia) (N19: eGFR or persistent)
- • Secondary Urea nitrogen - high (uremia/prerenal azotemia) clinical sign: fluid retention in in Urea nitrogen - high (uremia/prerenal azotemia) (N19: ankles, hands, or)
- • Symptom flares in Urea nitrogen - high (uremia/prerenal azotemia) correlating with Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) deviation outside K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N19)
- • Functional kidney & renal impact requiring strict blood pressure/glycemic in Urea nitrogen - high (uremia/prerenal azotemia) (N19: control) evaluation (N19)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Urea nitrogen - high (uremia/prerenal azotemia) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N19 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Urea nitrogen - high (uremia/prerenal azotemia) (N19: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Urea nitrogen - high (uremia/prerenal azotemia) (N19: Cystatin C)) | >= 90 mL/min/1.73m2 (N19) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Urea nitrogen - high (uremia/prerenal azotemia) (N19: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N19) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Urea nitrogen - high (uremia/prerenal azotemia)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ravicti (Glycerol Phenylbutyrate) Ravicti • RxCUI RXN-B75987050 | Nitrogen Binding Agent | 89% | $3.4500 | $ 256.90 /mo |
| Glycerol Phenylbutyrate Oral Glycerol Phenylbutyrate Oral Generic • RxCUI 1368453 | Nitrogen Binding Agent | 93% | $1.1000 | $ 53.05 /mo |
| Sodium Phenylacetate and Sodium Benzoate Sodium Phenylacetate and Sodium Benzoate Generic • RxCUI 2560228 | Nitrogen Binding Agent | 74% | $2.5800 | $ 112.99 /mo |
| Buphenyl (Sodium Phenylbutyrate) Buphenyl • RxCUI 213196 | Nitrogen Binding Agent | 92% | $1.9200 | $ 307.97 /mo |
| Sodium Phenylbutyrate Tablets, 500 Mg Sodium Phenylbutyrate Tablets, 500 Mg Generic • RxCUI RXN-49884170-2763 | Nitrogen Binding Agent | 86% | $1.7100 | $ 77.75 /mo |
| Pheburane (Sodium Phenylbutyrate) Pheburane • RxCUI 2610128 | Nitrogen Binding Agent | 85% | $2.4200 | $ 182.74 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Urea nitrogen - high (uremia/prerenal azotemia))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in: What a 4,300-Participant Study Found Despite similar glycemic efficacy in a relatively short term, SGLT2 inhibitors are more effective in the longer term than SUs as add-on to metformin. Clinical drug investigation • 2019-06-15 • Meta-Analysis | N = 4,300 | 94/100 | PMID 31041606 ↗ |
| New Insights on Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in: What a 466-Participant Study Found Among 1864 patients randomized (mean age, 58 [SD, 10] years; mean baseline HbA1c, 8.3% [SD, 0.9%]; mean body mass index, 32.5 [SD, 6.4]; n=879 [47.2%] women), 1758 (94.3%) completed the trial and 298 prematurely discontinued... JAMA • 2019-04-16 • Phase III Randomized Trial | N = 466 | 93/100 | PMID 30903796 ↗ |
| New Insights on Lixisenatide treatment improves glycaemic control in Asian patients with type 2: What a 391-Participant Study Found In Asian patients with type 2 diabetes insufficiently controlled on metformin ± sulfonylurea, lixisenatide significantly improved glycaemic control and was well tolerated during the 24-week study. Diabetes/metabolism research and reviews • 2014-11-15 • Randomized Controlled Trial | N = 391 | 93/100 | PMID 24639432 ↗ |
| New Insights on Prostacyclin analog beraprost sodium efficacy in primary glomerular disease or: What a 892-Participant Study Found TRK-100STP was generally well tolerated and most adverse drug reactions were mild or moderate in severity. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy • 2021-10-15 • Phase III Randomized Trial | N = 892 | 93/100 | PMID 33340238 ↗ |
| What the Latest Evidence Really Says About Benefits and safety of sodium-glucose cotransporter 2 inhibitors as add-on to Incidence of low blood sugar was significantly higher, but incidence of high blood sugar was significantly lower in SGLT2 inhibitor group. Endocrine journal • 2018-03-28 • Meta-Analysis | Multi-cohort | 92/100 | PMID 29375082 ↗ |
Urea nitrogen - high (uremia/prerenal azotemia) Patient Community & “People Like Me” Threads
Filter Urea nitrogen - high (uremia/prerenal azotemia) community threads and patient logs by age, biological sex, dosage, and treatment duration.